The Shares of one of the leading fixed-dosage injectable manufacturers around the world gained 4 percent in the day trade upon securing new marketing authorizations for its products in Malta, Europe.
At 12:59 p.m the shares of Venus Remedies Limited were trading at Rs. 417.90, up 1.96 percent from its previous day’s close price of Rs. 409.85 and its market capitalization is Rs. 558 Crores. It has delivered multibagger returns of 138 percent in a year.
Venus Remedies Limited has secured new marketing authorizations for Docetaxel and Gemcitabine in Malta, Europe. This authorization will help in expanding its pharmaceutical portfolio, and market presence and contribute to the advancement of healthcare solutions.
Venus Remedies is an Indian pharmaceutical company with a presence in domestic and international markets, it is among the top 10 leading fixed-dosage injectable manufacturers around the world. It is primarily engaged in the business of manufacturing pharmaceutical Products.
Its revenue from operations declined 7.44 percent from Rs. 600.18 Crores in FY22 to Rs. 555.51 Crores in FY23, accompanied by profits of Rs. 40.72 Crores to Rs. 26.57 Crores.
It has reported a return on equity (ROE) of 5.90 percent and a return on capital employed (ROCE) of 7.75 percent, it is making decent returns on its equity and capital employed.
According to the latest shareholding data available for the quarter ended December 2023, the company’s Promoters hold 41.76 percent stake, the Foreign Institutional Investors (FII) hold 1.59 percent.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
